Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

The Emirates Drug Establishment (EDE) has approved new indications for Guselkumab, making the UAE the second country globally to authorise the ...

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD). In GALAXI 2 (N=361) and GALAXI 3 (N ...

Guselkumab is the first IL-23 inhibitor approved for Crohn's disease with subcutaneous and intravenous options, targeting inflammation by blocking IL-23 and binding to CD64. The GRAVITI study ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis.

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study ...

The US Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderate to severe active Crohn’s disease (CD). The approval marks the ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's ...

Patients with moderate to severe psoriasis treated with ustekinumab and guselkumab showed a trend towards a lower risk for herpes zoster (HZ) and postherpetic neuralgia (PHN) than those receiving ...